Search by keywords: Connect with us Stay Informed. Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters. Newsletter Sign Up COVID-19: Information for Patients and Caregivers We're here for you, and continue to provide cancer care to new and current patients. Learn about our response to COVID-19.What you need to know 1719 News Items found Medical Oncologist Bob Li Featured in the Presidential Symposium at the 2020 World Conference on Lung Cancer Friday, January 29, 2021 Dr. Bob Li will present registrational phase II data from the first-ever trial of a drug that blocks cancer gene KRAS. Sloan Kettering Institute Scientists Solve a 100-Year-Old Mystery about Cancer Thursday, January 21, 2021 Scientists have long known that cancer cells and immune cells have an uncommon hunger for glucose but haven’t understood why. A new study offers an answer. Upcoming Clinical Trial Will Test New Cell Therapy for Parkinson’s Disease in Humans Friday, January 15, 2021 Study will be the first clinical trial testing an investigational stem cell therapy aimed at restoring lost brain cells called neurons in people with advanced Parkinson’s disease (PD). Finding Repairing DNA Damage in Cancer Cells Monday, January 11, 2021 New findings could lead to a different kind of cancer drug that targets a DNA damage repair pathway called nucleotide excision repair. Confronting a Crisis: How MSK Cancer Geneticists Responded to COVID-19 Friday, January 8, 2021 During World War II, US factories famously converted their operations to support the war effort. COVID-19 instigated something similar among cancer scientists. Memorial Sloan Kettering’s Martin S. Tallman, MD, Named American Society of Hematology President Friday, January 8, 2021 Dr. Tallman will serve a year-long term as President for the American Society of Hematology. Novel Treatment Pioneered by MSK Kids Researchers Receives FDA Approval for Patients with High-Risk Neuroblastoma Tuesday, January 5, 2021 The US Food and Drug Administration (FDA) has approved the drug naxitamab (Danyelza) for the treatment of patients with high-risk neuroblastoma. The drug, also known as humanized 3F8, was developed by researchers at MSK Kids, the pediatric cancer program at Memorial Sloan Kettering. Decoding the Biology of Brain Tumors Friday, January 1, 2021 Brain cancer is deadly because it’s so difficult to study. Scientist Luis Parada has developed an innovative model to analyze how brain tumors form and respond to treatment. Donors on a Mission to Fast-Track Cancer Therapies at MSK Friday, January 1, 2021 Meet Fiona and Stanley Druckenmiller, whose latest venture supports promising new avenues of research for experts at Memorial Sloan Kettering Cancer Center. Luis Diaz’s Vision: Treating Cancer Earlier — Even Before It Develops Friday, January 1, 2021 Luis Alberto Diaz, Jr. has dedicated his life’s work to addressing some of the most pressing challenges in cancer research — driven by one clear aim. Pagination Load More Book traversal links for Newsroom Previous Newsroom Next Cody's Story: How the MSK Kids Rare Tumor Program Benefited a Teenager With Advanced Kidney Cancer